iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
March 06 2024 - 7:01AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients,
today announced the appointment of Jill DeSimone to its Board of
Directors, effective March 7, 2024, where she will serve on the
Company’s audit committee.
“Expanding our board with industry leaders and
oncology veterans with commercial, scientific, and corporate
portfolio strategy experience is of the utmost importance for
iTeos. After the recent appointment of Servier’s David Lee, we are
thrilled to welcome Jill DeSimone to our Board of Directors during
an important time in iTeos’ evolution. Jill and David’s unique
insights will be of tremendous value to our organization as we
continue on our path to becoming a late-stage biopharmaceutical
company,” said Michel Detheux, Ph.D., president and chief executive
officer of iTeos.
“By leveraging its comprehensive knowledge of
tumor biology, iTeos has advanced a portfolio of promising
therapeutic candidates addressing key immunological pathways
involved in the development of cancer,” said Ms. DeSimone. “I look
forward to working with the iTeos leadership team and offering my
global business and commercial insights to help the company achieve
its goal of bringing transformational therapies to patients living
with cancer.”
With over 40 years of global business expertise
in life sciences, Ms. DeSimone is recognized for her role as
President of U.S. Oncology at Merck & Co., Inc., where she
established the company’s oncology division, growing it from less
than $500 million in annual revenue to $9 billion in eight years.
Additionally, she led three key product launches and more than 45
indication launches, including Keytruda®, the fastest growing
product in the company’s history. Prior to joining Merck, Ms.
DeSimone was Senior Vice President of Global Women’s Health at Teva
Pharmaceutical Industries, Ltd. She began her career at Bristol
Myers Squibb and held roles of increasing responsibility
culminating as the Senior Vice President of U.S. Oncology, a role
in which she helped launch the first FDA-approved CTLA-4 immune
checkpoint inhibitor, Yervoy®. Ms. DeSimone currently serves as a
board member for Affini-T Therapeutics, Inc., Kinnate Biopharma
Inc., Oncternal Therapeutics, Inc., Praxis Precision Medicine,
Inc., as well as the Florida Cancer Specialists Foundation, a
nonprofit organization that delivers non-medical aid for
individuals undergoing treatment for cancer, and Swim Across
America, a foundation that awards grants to cancer research and
patient programs. She earned a B.S. in Pharmacy from Northeastern
University and completed a fellowship with the Wharton School of
the University of Pennsylvania.
About iTeos Therapeutics,
Inc.iTeos Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to restore the immune response
against cancer. The Company’s innovative pipeline includes three
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes, including the TIGIT/CD226 axis and the
adenosine pathway. iTeos Therapeutics is headquartered in
Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of
InformationiTeos routinely posts information that may be
important to investors in the 'Investors' section of its website
at www.iteostherapeutics.com. The Company encourages investors
and potential investors to consult our website regularly for
important information about iTeos.
Forward-Looking StatementsThis
press release contains forward-looking statements. Any statements
that are not solely statements of historical fact are
forward-looking statements. Words such as “believe,” “anticipate,”
“plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,”
“potential,” “possible” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements include statements relating to the potential benefits of
product candidates; the value our new board members bring to iTeos;
and iTeos’ path to becoming a late-stage biopharmaceutical
company.
These forward-looking statements involve risks
and uncertainties, many of which are beyond iTeos’ control. Actual
results could materially differ from those stated or implied by
these forward-looking statements as a result of such risks and
uncertainties. Known risk factors include the following: market
conditions; challenges and uncertainties inherent in product
research and development and manufacturing limitations; the data
for our product candidates may not be sufficient for obtaining
regulatory approval to move into later stage trials or to
commercialize products; iTeos may not be able to execute on its
business plans, including meeting its expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing its product candidates to market,
for various reasons, some of which may be outside of iTeos’
control, including possible limitations of company financial and
other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, negative
developments in the field of immuno-oncology, such as adverse
events or disappointing results, including in connection with
competitor therapies, and regulatory, court or agency decisions
such as decisions by the United States Patent and Trademark Office
with respect to patents that cover our product candidates; and
those risks identified under the heading “Risk Factors” in iTeos’
Annual Report on Form 10-K for the year ended December 31, 2023
filed with the Securities and Exchange Commission (SEC) as well as
other SEC filings made by the Company which you are encouraged to
review. Statements regarding the Company’s cash runway do not
indicate when or if the Company may access the capital markets.
Any of the foregoing risks could materially and
adversely affect iTeos’ business, results of operations and the
trading price of iTeos’ common stock. We caution investors not to
place considerable reliance on the forward-looking statements
contained in this press release. iTeos does not undertake any
obligation to publicly update its forward-looking statements other
than as required by law.
For further information, please contact:
Investor Contact:Carl MauchiTeos Therapeutics,
Inc.carl.mauch@iteostherapeutics.com
Media Contact:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Jul 2024 to Aug 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2023 to Aug 2024